Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Roctavian Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.12

    Roctavian (valoctocogene roxaparvovec-rvox) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.12 alerts

    Get alerted when Policy 05.05.12 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Roctavian in adults with severe congenital hemophilia A. Coverage requires clinical, laboratory, prescriber, liver-health, and treatment-history criteria and is limited to one treatment per lifetime.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyRoctavian (valoctocogene roxaparvovec-rvox)
    Policy CodePolicy 05.05.12
    Change TypeNo material clinical or coverage changes
    Effective DateJan 1, 2024
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical records and laboratory results supporting all applicable eligibility criteria for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    ≤1 IU/dL

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum factor VIII activity
    1 doseTreatment limit
    12 monthsPrior factor VIII prophylaxis
    6 × 10^13 vg/kgRecommended dose

    Coverage Criteria

    Initial therapy for severe hemophilia A

    Covered for severe hemophilia A when ALL of the following criteria are met:

    Covered benefit conditions

    • All applicable approval criteria must be met and the member must have no exclusions to the prescribed therapy.

    Continuation therapy

    Repeat treatment is considered investigational and is not covered.

    Continuation or repeat therapy

    • Roctavian may not be repeated for any indication because safety and efficacy beyond one dose have not been studied.

      Repeat treatment is limited to one treatment course per lifetime.

    Repeat treatment of Roctavian for any indication is considered investigational because safety and efficacy beyond one dose have not been studied. Repeat treatment is therefore excluded from coverage.

    Coverage is limited to one treatment course per lifetime. Treatment exceeding one course is excluded.

    Roctavian is not medically necessary when the member does not meet the coverage criteria set forth in this policy.

    Coding and Clinical Parameters

    HCPCS code for RoctavianHCPCSCovered
    J1412Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes (effective 1/1/24)
    Unclassified drug and biological codesHCPCS
    J3590Unclassified biologicals
    C9399Unclassified drugs or biologicals
    Factor VIII Activity
    Factor VIII activity threshold≤1 IU/dL
    Clinical significanceRequired for severe hemophilia A coverage
    DocumentationChart notes, medical records, or laboratory results must document the factor VIII activity level
    Factor VIII Inhibitor Titer
    Inhibitor titer threshold<0.6 Bethesda Units
    Required assayNijmegen-Bethesda assay
    Coverage requirement

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Roctavian may be authorized. Submit chart notes, medical records, laboratory results, and other supporting documentation establishing eligibility for the one-dose treatment course; authorization may be granted for 1 month for one dose total when all policy criteria are met.

    • Document that the member is at least 18 years of age and was assigned male at birth.
    • Document at least 12 months of factor VIII prophylaxis, such as Advate, Adynovate, Eloctate, or Hemlibra.
    • Document that Roctavian is prescribed by or in consultation with a hematologist or a prescriber who specializes in hemophilia A.
    Documentation Required

    Required Clinical and Laboratory Records

    Provide clinical and laboratory records confirming severe hemophilia A and the required antibody and inhibitor results.

    Background

    Roctavian (valoctocogene roxaparvovec-rvox) is a gene therapy indicated for adults with severe congenital hemophilia A. Severe disease is defined by factor VIII activity of ≤1 IU/dL.

    Definitions

    Severe Hemophilia A
    ConditionSevere hemophilia A
    Underlying deficiencyCongenital factor VIII deficiency
    Factor VIII activityLess than 1 IU/dL
    Factor VIII Inhibitor Threshold
    Inhibitor titerLess than 0.6 Bethesda Units
    AssayNijmegen-Bethesda assay
    Eligibility statusNo prior or active factor VIII inhibitors

    Initial Therapy Criteria

    Initial approval for severe hemophilia A

    Authorization of 1 month for one dose total may be granted when ALL of the following criteria are met:

    Initial approval requirements

    • Member is 18 years of age or older and was assigned male at birth.Age ≥18
    • Member has severe hemophilia A with factor VIII activity less than or equal to 1 IU/dL.Factor VIII activity ≤1 IU/dL
    • Member does not have pre-existing antibodies to AAV5, confirmed by an FDA-approved test.
    • Member does not have prior or active factor VIII inhibitors; the inhibitor titer must be less than 0.6 Bethesda Units using the Nijmegen-Bethesda assay.

    Continuation Criteria

    No repeat treatment

    Repeat treatment is not covered.

    One-time therapy limit

    • Repeat treatment of Roctavian for any indication is considered investigational because safety and efficacy beyond one dose have not been studied.

      Approval is limited to one treatment course per lifetime.

    Quantity Limits

    Roctavian Quantity Limit
    Treatment limitOne treatment per lifetime
    Repeat treatmentRoctavian approvals are limited to one treatment per lifetime
    Quantity-limit basisApplies to Roctavian
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyRoctavian (valoctocogene roxaparvovec-rvox)
    Policy CodePolicy 05.05.12
    Change TypeNo material clinical or coverage changes
    Effective DateJan 1, 2024
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical records and laboratory results supporting all applicable eligibility criteria for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Actions and DocumentationBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits
    The member must not have a prior or active factor VIII inhibitor
    Prior Factor VIII Prophylaxis
    Required durationAt least 12 months
    TherapyFactor VIII prophylaxis
    ExamplesAdvate, Adynovate, Eloctate, and Hemlibra
    Roctavian Dose
    Recommended dose6 × 10^13 vector genomes
    Weight basisPer kilogram of body weight
    Dosing standardApprovals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines
    • Factor VIII activity level ≤ 1 IU/dL.
    • No pre-existing antibodies to the AAV5 capsid, confirmed by an FDA-approved test such as AAV5 DetectCDx™.
    • No prior or active factor VIII inhibitor; inhibitor titer must be 0.6 Bethesda Units (BU) using the Nijmegen-Bethesda assay. Bethesda assay laboratory results are required.
    Documentation Required

    Pretreatment Assessment

    Complete and document the pretreatment assessment before requesting Roctavian, including liver-health testing, hepatic imaging, elastography, and infection- and thrombosis-related assessment.

    • Liver enzymes and related testing: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin.
    • Hepatic ultrasound and elastography.
    • No active hepatitis B or hepatitis C infection; document that the member is HIV negative.
    • No history of thrombosis or thrombophilia.
    Prior Authorization

    Prophylaxis Discontinuation Attestation

    Attest that regular factor VIII prophylactic therapy will be discontinued after gene therapy once the appropriate time has elapsed for factor VIII levels to reach therapeutic levels after steady state.

    Documentation Required

    Post-Infusion Counseling Attestation

    Attest that the member has been counseled about the risks of alcohol consumption and concomitant hepatotoxic medications after Roctavian and agrees to abstain from alcohol for at least 1 year after infusion.

    Prior Authorization

    Evio Outcome Reporting

    For an approved Roctavian treatment, the requesting physician must attest to providing clinical outcome information through the Evio provider portal at the cadence requested by the platform.

    • Evio captures clinical outcome information for selected high-cost treatments, including gene and cellular therapies.

    Unsupported block type: denial_risk

    Denial Risk

    Failure to Meet Criteria

    Roctavian is not medically necessary when the member does not meet all applicable policy criteria.

    • Requests lacking required clinical, laboratory, pretreatment, or provider-attestation documentation may not meet medical-necessity requirements.
    Denial Risk

    Prior Treatment or Lifetime Limit

    Coverage may be denied when the member has previously received Roctavian or when the request exceeds the policy limit of one treatment course per lifetime.

    • Document that the requested medication has not been administered previously.
    • The lifetime limit applies regardless of the indication for repeat treatment.
    AAV5 Antibody Status
    Antibody statusPre-existing antibodies to the AAV5 capsid must be absent
    ConfirmationConfirmed by an FDA-approved test
    Virus designationAdeno-associated virus serotype 5 (AAV5)
    Inhibitor titer <0.6 Bethesda Units
  1. Member has been receiving factor VIII prophylaxis for at least 12 months.Factor VIII prophylaxis ≥12 months
  2. Member has received a liver health assessment, including ALT, AST, ALP, and total bilirubin testing, a hepatic ultrasound, and elastography.
  3. Member does not have active hepatitis B and/or hepatitis C infection, is HIV negative, and does not have a history of thrombosis or thrombophilia.
  4. Member has not previously received Roctavian.
  5. Roctavian is prescribed by or in consultation with a hematologist or a prescriber who specializes in hemophilia A.
  6. The provider attests that regular prophylactic therapy will be discontinued following the appropriate time frame for factor VIII levels to reach therapeutic levels after steady state, after the member has received gene therapy.
  7. The provider attests that the member was counseled regarding the risks of alcohol consumption and concomitant hepatotoxic medications after Roctavian and agrees to abstain from alcohol consumption for at least 1 year following infusion.Alcohol abstinence ≥1 year following infusion